Page URL:

Ten years on - personal genome sequencing for under £50K

15 June 2009
Appeared in BioNews 512

The age of affordable genome sequencing is inching ever closer, spurred on last week by the announcement that San Diego biotech firm Illumina is launching its personal sequencing service for under $50,000. Speaking at the Consumer Genetics Show in Boston, Massachusetts, US, Jay Flatley - the president and CEO of Illumina - unveiled a service that represents the first time that an individual's genome can be sequenced so thoroughly, for such a (relatively) low price.

Illumina has offered basic genotyping services since 2001 - reading a customer's SNPs (single nucleotide polymorphisms) and relating these to specific disease traits - but is better known as supplier of the popular sequencer instrument - Genome Analyzer II - to both academic and industry sectors. In February, Flatley predicted that babies' genomes would be sequenced at birth by 2019, given the current rate of sequence development, fueling rumours that Illumina would soon enter the whole-genome sequencing market itself.

Conceding that demand for such an 'information goldmine' may not yet be huge, an optimistic Flatley nonetheless proposes that the current market potential could be on the order of hundreds of customers. 'We think there is quite a number of people who want to be among the first ten named genomes in the world, or the first 100, or the first 1,000, so I think there is some market here', he said.

In a move deemed as pragmatic yet naive, the service will only be available via referral from a physician. Direct-to-customer (DTC) sequencing remains controversial, as customer anonymity might more easily be comprised should no doctor be stationed as mediator and, furthermore, patients may not be in a position to make informed decisions in response to unanticipated results. Germany has recently passed a law against any DTC sequencing operations. However, prescriptions are available to customers via Illumina's website, where customers can choose from a list of physicians allied to the firm.

Increasingly rapid sequencing will ostensibly drain the market, as individuals will need their genome sequencing just once. The arguably more interesting service - the interpretation - is being left by Illumina to third-party firms, like part Google-financed 23andMe, deCODEme and Navigenics, who will calculate disease risks, ancestries and other traits of interest, based on the literature. Whilst sequencing will one day reach a peak, interpretation will be an ever-evolving market, as our understanding of the human genome expands. Illumina has yet to invest in this field.Flatley also unveiled a prototype iPhone app that would allow doctor and customer to share and analyse sequencing results, fitted with a biometric ID system to ensure data protection.

Gene sequencing will cost $1,000 in about 2 years, scientists predict
Boston Herald |  10 June 2009
Genomes! Get Your Genomes! Just $50K |  10 June 2009
Illumina Announces Personal Genome Sequencing Service (press release)
Earth Times |  10 June 2009
8 October 2012 - by Paola Quattroni 
A computer-based platform which looks to greatly speed up genetic analysis of tumours has been unveiled in the USA. Currently such analysis can take up to eight weeks, the new platform promises to deliver results in just 47 seconds...
16 January 2012 - by Dr Zara Mahmoud 
A US biotechnology firm has unveiled an automated desktop DNA sequencer that can decode the sequence of the human genome in one day for as little as $1,000 (£650). Given its first public viewing at a consumer electronics show in Las Vegas, Life Technologies Corporation's Ion Proton sequencer uses microchips similar to those found in digital cameras...
4 May 2010 - by Dr Sophie Pryor 
Whole genome analysis has been used for the first time to gather clinically-useful information about the risk of developing diseases later in life. Stephen Quake, an apparently healthy, middle-aged professor of bioengineering at Stanford University in California, volunteered to have his entire genetic code screened. He was found to be at increased risk of developing diabetes, some cancers and of having a heart attack...
3 August 2009 - by Dr Charlotte Maden 
People who have had their genome scanned to find the relative risks of them developing common genetic disorders may find themselves more or less at risk now than when they had the test done, even if thier lifestyle hasn't changed. This is due to more discoveries being made in the genetics field, and since it is often not understood by the individual, has resulted in calls for tighter regulations for the testing....
26 July 2009 - by Rosie Beauchamp 
Personal 'genome scans' have been in the news again, not because they are a particularly new phenomenon but because the data they provide is about to take on a new significance. Up until now, genetic tests looking for variations associated with diseases have been available over the Internet for those who have been willing to pay the fee - usually a few hundred dollars....
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.